1 Reason Why Cronos Group Inc (TSX:CRON) Is Prepared for Hyper Cannabis Growth

Cronos Group Inc (TSX:CRON)(NASDAQ:CRON) has the backing of Altria Group Inc (NYSE:MO), giving it a permanent competitive edge.

| More on:
woman data analyze

Image source: Getty Images.

In December, shares of Cronos Group Inc (TSX:CRON)(NASDAQ:CRON) popped more than 10% as rumours began swirling that Altria Group Inc (NYSE:MO) was readying a bid to acquire the entire company. With a $90 billion market capitalization and decades of experience navigating heavily regulated industries, the tie-up would have created a cannabis behemoth.

Soon after, Cronos released a statement confirming that it is “engaged in discussions concerning a potential investment by Altria Group Inc.” Shares rose by another 14%. Three days later, Cronos shares were halted “pending the release of news.”

Finally, on December 7, Altria announced that it would take a 45% stake in Cronos for $2.4 billion, which worked out to $16.25 per share, 40% lower than current levels.

Cronos is now the leader in cannabis

The New York Times recently ran an article predicting large firms, particularly tobacco companies, will be “unlikely to make major moves in the American market until recreational use of THC products is legal at a federal level.” This makes Altria’s deal with Cronos all the more valuable.

Entering the cannabis market is still fraught with difficulties, particularly because marijuana remains illegal at a federal level. While pot companies like Hexo Corp (TSX:HEXO) have the blessings of their national governments, Altria is paying billions of dollars to participate in a federally illegal market. This is truly a risk, but one that should pay off big for both companies.

An analyst at Cowen predicts that the cannabis market in the U.S. will reach $80 billion by 2030. Altria generated $29.6 billion in cigarette sales last year, so winning a piece of the cannabis pie could make a big difference.

If and when cannabis becomes legal on a federal level in the U.S., companies with the deepest pockets, largest distribution networks, and strongest knowledge of highly-regulated markets will win. That’s why so many large names have scrambled into the CBD market lately. Today, there isn’t a cannabis competitor that’s better positioned than the Altria and Cronos partnership.

A full buyout is very possible

Notably, when Altria acquired its 45% in Cronos, it also received warrants to acquire an additional 10% stake for $19 per share. With current prices well in excess of that strike price, Altria will surely exercise their rights. While it may take some time for this to occur, Altria taking a controlling stake in Cronos is seemingly inevitable.

Once this happens, acquiring the entire company is a real possibility. Altria group already has control over the company, and maintaining two public entities requires additional compliance, regulation, and costs. If the future of Cronos is bright enough to warrant boosting its position by 10%, it would make sense for Altria to go all the way, acquiring 100% of shares.

In this case, a large premium will need to be paid to acquire the remaining 45% of Cronos stock, which is one reason why shares rallied nearly 100% since Altria took its initial stake.

Either way, the future looks bright. With Altria as a partner, Cronos is one of the best-positioned cannabis stocks in a high growth industry. Over time, shareholders have a real chance at cashing in early via a complete buyout.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ryan Vanzo has no position in any stocks mentioned.

More on Investing

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

young woman celebrating a victory while working with mobile phone in the office
Investing

3 Roaring Stocks to Hold for the Next 20 Years

These top TSX stocks are excellent long-term buys, given their multi-year growth potential and solid underlying businesses.

Read more »

Two seniors float in a pool.
Dividend Stocks

TFSA: How to Earn $1,890 in Annual Tax-Free Income

Plunk these investments into your TFSA to earn passive income and avoid the taxman.

Read more »

grow dividends
Investing

Here’s My Top 3 TSX Stocks to Buy Right Now

Even though the TSX has been rising, there are still some good bargains out there. Here are three top compounding…

Read more »

Target. Stand out from the crowd
Investing

Prediction: This Canadian Growth Stock Could Double by 2030

Alimentation Couche-Tard (TSX:ATD) is a top growth stock that could do well over the next six or so years.

Read more »

Businessman holding AI cloud
Tech Stocks

Could Investing $20,000 in Nvidia Make You a Millionaire?

Nvidia stock has made investors millionaires in the last 10 years. Is it too late to invest to become a…

Read more »

Engineers walk through a facility.
Dividend Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

AtkinsRéalis (TSX:ATRL) is one TSX stock I'd never invest in.

Read more »

money cash dividends
Stocks for Beginners

Have $500? 3 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now

If you're looking for cheap stocks, these three have a huge future ahead of them, all while costing far less…

Read more »